Norgine Celebrates TGA Approval of IFINWIL® for High-Risk Neuroblastoma Patients in Australia Norgine announces the approval of IFINWIL® by Australia's TGA for treating high-risk neuroblastoma, marking a significant advancement for pediatric cancer care.

Norgine Celebrates TGA Approval of IFINWIL® for High-Risk Neuroblastoma Patients in Australia #Australia #Neuroblastoma #Norgine #IFINWIL #Ugxbridge